Kite Pharma:Focused on the CureArie Belldegrun, MD, FACSChairman, President, & Chief Executive Officer

2

Forward Looking Statements/Safe HarborTo the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc.(“Kite,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause ouror our industry’s actual results, levels or activity, performance, or achievements to be materially different from thoseanticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,”“could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negativeof those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statementscontained in this presentation include, but are not limited to, statements regarding: (i) the success and timing of ourproduct development activities and clinical trials; (ii) the ability and willingness of the National Cancer Institute (NCI) tocontinue research and development activities relating to our product candidates; (iii) our ability to obtain and maintainregulatory approval of KTE-C19 and any other product candidates; (iv) our ability to further develop and commercialize ourproduct candidates; (v) our plans to research, discover and develop additional product candidates, including through oursubsidiary Kite Pharma EU, and next generation product candidates, including a next-generation CAR with an “on/off”switch; (vi) our and our partners’ ability to develop, manufacture and commercialize our product candidates and to improvethe manufacturing process; (vii) the size and growth potential of the markets for our product candidates, and our ability toserve those markets; (viii) the rate and degree of market acceptance of our product candidates; (ix) our ability to attract andretain key scientific or management personnel; (x) the anticipated timing of clinical data availability; (xi) the anticipatedtiming of commercial launch of KTE-C19; (xii) our plans to expand geographically; (xiii) our ability to meet the milestonesset forth herein and (xiv) our expectations regarding our ability to obtain and maintain intellectual property protection forour product candidates.

Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite'sfilings with the Securities and Exchange Commission (SEC), including without limitation in its Quarterly Report on Form 10-Q filed with the SEC on May 9, 2016. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall notconstitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any stateor jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under thesecurities laws of any such state or jurisdiction.

Changing

Empowering

Utilizing

Advancing

Optimizing

Building

Kite: Focused on the Cure

a patient’s own immune system to combat cancer

two technology platforms to address both hematologic and solid tumors

our lead product candidate in four pivotal studies and preparing for 2017 commercial launch

and automating in-house manufacturing to bring cell therapies to the broad market

a pipeline of future cancer therapies with innovative internal R&D and collaborations with select industry leaders

the paradigm of cancer treatment

3

Developing The Ultimate Personalized Cancer Immunotherapy

4

ENGINEERED AUTOLOGOUS CELL THERAPY (eACT™)

Apheresis ManufacturingProcess

Infusion

5

Dual Platform Targets Both Hematological and Solid Cancers

Chimeric Antigen Receptor (CAR)Targets molecules on

the cell surface

T Cell Receptor (TCR)Targets molecules at or below the cell surface

6

Kite Pharma: An Industry Leading Pipeline of CAR and TCR Product Candidates

DLBCL = diffuse large B cell lymphomaPMBCL = primary mediastinal B cell lymphomaTFL = transformed follicular lymphomaMCL = mantle cell lymphoma

ALL = acute lymphoblastic leukemiaFL = follicular lymphomaCLL = chronic lymphocytic leukemia

CHIMERIC ANTIGEN RECEPTOR (CAR)PRE-IND PHASE 1 PHASE 2

KTE-C19 DLBCL, PMBCL, TFL (ZUMA-1)

KTE-C19 MCL (ZUMA-2)

KTE-C19 Adult & Pediatric ALL (ZUMA-3, ZUMA-4)

KTE-C19 2nd Wave of ZUMA Studies Combination, FL, CLL

Human Anti-CD19Heme malignancies

Amgen Multi-Target Collaboration Heme malignancies

Amgen Multi-Target Collaboration Solid tumors

T CELL RECEPTOR (TCR)PRE-IND PHASE 1 PHASE 2

MAGE A3/A6 Solid tumors

MAGE A3 Solid tumors

HPV-16 E6 Cervical and head & neck cancer

HPV-16 E7 Cervical and head & neck cancer

NY-ESO-1 Solid tumors

SSX2 Solid tumors

KRAS KRAS mutation tumors

NEO-ANTIGENS Solid tumors

Kite: Investigating Targets with Broad Clinical Applicability

7

CD19

• Non-Hodgkin Lymphoma

• Leukemias

NY-ESO-1HPV-16 E6/E7 SSX2 KRAS Neo-Antigens

• Urothelial• Sarcoma• Lung• Melanoma

• Lung• Pancreatic• Gastric• Breast

• Cervical• Head & Neck• Anal Cancer

• HCC• Melanoma• Prostate• Sarcoma

• Pancreatic• CRC• Lung

• Potentially all types of cancer

TCRsCARs

MAGE A3/A6

Kite Targets from Amgen Collaboration

• AML• MM• Kidney• Lung

Executive Management and Scientific Team Have a Proven Track Record of Success

8

Scientific Advisory BoardOwen N. Witte, MD (Chairman)UCLA

Ronald Levy, MD Stanford School of Medicine

James Allison, PhDThe University of Texas MD Anderson Cancer Center

Antoni Ribas, MD, PhDUCLA

James Economou, MD, PhDUCLA

Padmanee Sharma, MD, PhDThe University of Texas MD Anderson Cancer Center

Zelig Eshhar, PhDTel Aviv Sourasky Medical Center & Weizmann Institute of Science

Inder Verma, PhDThe Salk Institute

Donald Kohn, MDUCLA

Special AdvisorSteven A. Rosenberg, MD, PhD

NCI/KITE CRADA

Kite Pharma EUTon N. M. Schumacher, PhDChief Scientific Officer

Executive ManagementArie Belldegrun, MD, FACSChairman, President and CEO

Cynthia M. ButittaChief Operating Officer

Paul JenkinsonChief Financial Officer

David D. Chang, MD, PhDEVP R&D, Chief Medical Officer

Shawn C. TomaselloChief Commercial Officer

Tim MooreEVP, Technical Operations

Helen S. KimEVP, Business Development

Margo R. Roberts, PhDChief Scientific Officer

Jeff Wiezorek, MD, MSSVP, Clinical Development

Chiron

Strategic Collaborations TCR

CAREnabling Technologies

Surgery Branch

Experimental Transplantation & Immunology Branch

Leveraging Academic and Industry Collaborations for Next Generation Technologies

9

Significant Accomplishments

10

• Initiated four KTE-C19 pivotal studies in DLBCL, MCL, adult, and pediatric ALL under two separate company INDs

• Received Breakthrough Therapy Designation for KTE-C19 under company IND in the US and PRIME Designation in the EU

• Secured Orphan Drug Designation for KTE-C19 in the US and EU for all our hematological indications

• Established European operations with T-Cell Factory acquisition, NKI agreement and launched Kite EU

• Built out the company with the addition of over 100 new hires, including the Chief Commercial Officer and EVP of Technical Operations

Building the Future of

Cancer Therapy11

DELIVER IN HEMATOLOGY• Four pivotal studies for

KTE-C19• ‘Second wave’ of KTE-

C19 studies • Commercial launch of

KTE-C19 in 2017 planned

FOCUS ON SOLID TUMORS

• 2016 IND for MAGE A3 • CAR product candidates

from Amgen collaboration • TCR GENEratorTM

technology for additional TCR product candidates

DEVELOP NEXT GEN.CELL THERAPY

• Combination therapy (Genentech)

• Modulating immune synapse using the vIgD technology (Alpine IS)

• Fully automated process (GE Global Research)

Introducing Control to CAR through Synthetic Biology

scFv, single-chain variable fragment; TCR, T cell receptor; ITAM, immunoreceptor tyrosine-based activation motif

A “SPLIT” CAR design that allows for a DIALABLE, INSTANT, and,REVERSIBLE control of CAR activity, in the presence of a small molecule

32

Ongoing ZUMA Studies to Support Registration of KTE-C19

13

Study Phase Indication Status

ZUMA-1 Phase 2 Pivotal(N=112)

DLBCLPMBCL

TFL

EnrollingInterim Data* 2016Primary Data 2017

ZUMA-2 Phase 2 Pivotal(N=70) MCL Enrolling

Data 2017

ZUMA-3 Phase 1/2 Pivotal(N=75) Adult ALL Phase 1/2 Enrolling

P2 Data 2017

ZUMA-4 Phase 1/2 Pivotal(N=75) Pediatric ALL Phase 1/2 Enrolling

P2 Data 2017

Additional studies in FL, CLL, earlier lines of DLBCL, and combination studies

starting in 2016

*If supported by data, plan to file Biologics License Application based on interim data

14

KTE-C19 Will Address Largest Unmet Need in NHL

*Ex-US incidence of DLBCL is 24,000 cases per year (France, Germany, Italy, Spain, UK, and Japan)

10,0004,600 1,400

26,000

15,700

6,000

DLBCL CLL ALL

Incidence per year

US deaths per year

US new cases per year

15

ZUMA-1 Phase 1 Clinical Data Show Ongoing CRs at 9-Month Follow-Up

Complete Response at Day 30

BaselineEfficacy• 71% Objective Response Rate (n=5/7)• 57% Complete Remissions (n=4/7)• 3 Complete Remissions ongoing at 9 months

Safety• 1 patient with DLT (grade 4 CRS and neurotoxicity)

died on study (unrelated to KTE-C19)• 14% grade 3+ CRS• 57% grade 3+ neurotoxicity• With the exception of the patient with DLT, all

grade ≥3 KTE-C19-related toxicities resolved

Neelapu et al, ASCO Annual Meeting 2016

SCHOLAR-1: the first and largest patient-level meta-analysis of chemorefractory DLBCL

SCHOLAR-1 is a retrospective analysis of 635 patients with chemorefractory DLBCL from 4 studies/institutions

Patients with chemorefractory DLBCL have consistently poor outcomes regardless of refractory subgroup, line of therapy, and disease stage

These data provide a historical benchmark for future studies in chemorefractory DLBCL

Median OS

6.6 months

Overall response rate

26% (18% PR & 8% CR)

17

NCI Data Demonstrating Breakthrough Efficacy in Aggressive NHL

17

Group (n) Best ResponseORR CR

All Patients (41)*† 78% 54%All Aggressive NHL (27) † 70% 48%

Aggressive NHL with low dose conditioning regimen (19) **‡ 68% 47%

Aggressive NHL with low dose conditioning regimen and Kite manufacturing process (13) † 69% 54%

†Data as of 11/30/15‡Data from ASCO 2016

**All CRs (9) are still in CR*8 patients converted from PR to CR

Generally reversible CAR-related grade 3-4 AEs

– CRS: All patients 30%, Kite manufacturing 31%– Neurotoxicity: All patients 44%, Kite

manufacturing 69%

18

Before treatment 10 months after treatment

Before treatment 10 months after treatment

18

DLBCL Patient 38 With an Ongoing CR That Had Progressed on R-ICE, GDP, and R-EPOCH

19

Manufacturing On Track for KTE-C19 Launch in 2017

In-house clinical manufacturing in full operation

Commercial facility in close proximity to LAX airport

Capacity to produce 4,000-5,000 patient therapies per year

Modular design is scalable and cost effective

Site to produce KTE-C19 and all TCR products

4 Ongoing Registration Studies in >40 Sites

9

21

TCRs Have the Potential to Access a Broad Spectrum of Therapeutic Tumor Targets

Potential CAR Targets(~27% Human Proteome)

Potential TCR Targets(All Human Proteome)

Proof of Concept for MAGE A3 TCR and HPV TCR

22

MAGE A3 is expressed in NSCLC, bladder, myeloma, SCC, melanoma, among others

3 responders (cervical, esophageal, and urothelial cancer) among 14 evaluable patients

No off-target toxicities

HLA-DPB1*0401 present in 40% to 70% of Caucasian population

PR: 85% Tumor Reduction

Pre-Treatment 12 Months

Cervical Cancer Patient100% Tumor Disappearance

HPV infection is associated with 5% of all cancers globally

Durable CR (22+ months) in cervical cancer patients treated with HPV reactive T cell therapy1

HPV-16 E6 TCR Phase 1 study at NCI showed a significant response (-90%) in a patient with anal cancer

HLA-A*0201 is present in 40% of the total US population

Pre-Treatment 15 Months

Lu, YCW, AACR Annual Meeting 20161 Stevanovic, 2015, J Clin Onc epub

Innovating the Next Generation of Products

23

Validate Target Selectivity Advance Cancer-Specific

Targets

Target Selection

Improve Target Fidelity of CAR/TCR Constructs

Modulate CAR/TCR Function in vivo

Reduce Immunogenicity

CAR/TCROptimization

Automate Manufacturing Selectively Expand Potent T

Cell Subsets ex vivo

Manufacturing

Overcome Immune Suppression

Combination Therapy Introduce Gene Editing or

Gene Modulation

Tumor Microenvironment

Optimize in vivo T Cell Expansion Improve Safety Management Identify Predictive Biomarkers for

Safety and Efficacy

Clinical Development

2016 Projected Milestones

Report interim data for Phase 2 ZUMA-1

File KTE-C19 BLA on interim data

Complete qualification/validation of manufacturing facility

Initiate KTE-C19 clinical studies in Europe

Initiate Phase 1b/2 combination study of Kite’s KTE-C19 and Genentech’s atezolizumab

File IND for first Kite TCR product: MAGE A3

25

Changing

Empowering

Utilizing

Advancing

Optimizing

Building

Kite: Focused on the Cure

a patient’s own immune system to combat cancer

two technology platforms to address both hematologic and solid tumors

our lead product candidate in four pivotal studies and preparing for 2017 commercial launch

and automating in-house manufacturing to bring cell therapies to the broad market

a pipeline of future cancer therapies with innovative internal R&D and collaborations with select industry leaders

the paradigm of cancer treatment

25